TCRX Projected Dividend Yield
TScan Therapeutics Inc ( NASDAQ : TCRX )TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate. 20 YEAR PERFORMANCE RESULTS |
TCRX Dividend History Detail TCRX Dividend News TCRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |